Browse News
Filter News
Found 509,529 articles
-
Swiss pharma giant Novartis is halting planned price increases on its medications after President Donald Trump took Pfizer to task over price hikes earlier this month. Pfizer agreed to roll back its price increases last week.
-
Two well-known pharmaceutical companies made Fortune Magazine’s 2018 top 100 Best Workplaces for Millennials.
-
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
-
Despite President Trump circling around semi-regularly to bash the pharmaceutical industry and drug prices, biotech stocks seem to be doing pretty well. The Nasdaq Biotechnology ETF, called the IBB, is up about 17 percent so far this year.
-
French biotech company Servier is setting up shop in Boston following its April deal to acquire Shire’s oncology business for $2.4 billion.
-
Pfizer and Eli Lilly released results from its 16-week Phase III clinical trial in patients with osteoarthritis (OA) pain receiving a subcutaneous dose of tanezumab. The drug hit all three co-primary endpoints.
-
Rubius Therapeutics, based in Cambridge, Massachusetts, has set the price of its initial public offering at $23 per share.
-
Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.
-
HIV patients have some good news this morning. The U.S. Food and Drug Administration approved Janssen Pharmaceutical’s Symtuza, the first and only complete darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1).
-
Absence epilepsy is the most common type of seizure disorder in children and is the focus of a new neurology study at Baylor College of Medicine and published in the journal Nature Communications.
-
Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal Cancer
7/18/2018
Voyager-V1 is being administered to inflame the tumors, and avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.
-
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
7/18/2018
Tanezumab is also being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
-
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®
7/18/2018
Genexine will conduct a phase 1b/2 clinical trial to investigate the safety and efficacy of Hyleukin-7 treatment in combination with Merck’s anti PD-1 therapy, KEYTRUDA® in patients with triple-negative breast cancer.
-
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
7/18/2018
Regulatory path to include Phase 3 trial expected to begin in 2019
-
Hu-Friedy Launches New Powder for AIR-FLOW® Therapy System
7/18/2018
Unique erythritol powder delivers a better way for dental professionals to efficiently remove stains and biofilm without damaging gums or implants
-
Viz.ai Raises $21 M in Series A Funding From Kleiner Perkins and GV to Increase Patient Access to Proven Therapies
7/18/2018
Viz.ai has built the first FDA cleared computer aided triage software to detect and triage urgent stroke cases.
-
Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients
7/18/2018
Leading Generic Pharmaceutical Company Increases Manufacturing Capacity to Produce and Release Significant Quantities of Scarce Medicines
-
National Life Insurance Company Announces Expiration Of And Results For Previously Announced Private Exchange Offer For Any And All Of Its Outstanding 10.50% Surplus Notes Due 2039
7/18/2018
National Life Insurance Company announced the expiration of and the results for its previously announced offer to exchange any and all of National Life's outstanding 10.50% Surplus Notes due 2039 held by Eligible Holders
-
Attorney Christopher Jacobs Appointed to Virginia Supreme Court's Medical Malpractice Review Panel
7/18/2018
On July 1, 2018, Attorney Christopher I. Jacobs of Kalfus & Nachman, P.C. was named a member of the Supreme Court of Virginia's Medical Malpractice Review Panel (MMRP).
-
BIO Applauds House Passage of the JOBS and Investor Confidence Act of 2018
7/18/2018
The JOBS and Investor Confidence Act of 2018, which includes the Fostering Innovation Act, provides much needed regulatory relief for pre-revenue innovators